CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY

policy pharmaceutical raw materials pharmaceutical

Authors

  • Erwan Hermawan
    erwanhermawan29@gmail.com
    Research Center for Process and Manufacturing Industry Technology - National Research and Innovation Agency, Serpong, Indonesia
  • Nur Anis Hadiyati Directorate of Research, Technology, and Innovation Policy Formulation – National Research and Innovation Agency, Jakarta, Indonesia
  • Adiarso Adiarso Research Center for Process and Manufacturing Industry Technology - National Research and Innovation Agency, Serpong, Indonesia
  • Ermawan Darma Setiyadi Research Center for Process and Manufacturing Industry Technology - National Research and Innovation Agency, Serpong, Indonesia
  • Siti Zunuraen Research Center for Marine and Land Bioindustry - National Research and Innovation Agency, Pemenang, Indonesia
  • Dudi Hidayat Research Center for Process and Manufacturing Industry Technology - National Research and Innovation Agency, Serpong, Indonesia
  • Anwar Wahyudi Ministry of Health, Jakarta, Indonesia
  • Hartini Ahadiyatur Ru’yi Directorate of Research and Innovation Infrastructure Partnership, National Research and Innovation Agency, Jakarta, Indonesia
November 9, 2023
policybrief

Downloads

Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives.

Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia

Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022.

Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D.

Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera.

Keywords: pharmaceutical raw materials, policy, pharmaceutical